Pretreatment screening

♦ The patient's disease should be in remission.

♦ There should be adequate renal, cardiac, hepatic, and pulmonary function to cope with the toxicity of chemotherapy and TBI.

♦ Exposure to medication with the same side-effects as TBI, or likely to potentiate its side-effects, should be assessed. Common interactions: neurotoxicity with asparaginase, renal with platinum or ifosfamide, pulmonary with methotrexate or bleomycin, cardiac with cyclosphosphamide or anthracyclines.

♦ The need for additional therapy to sites such as the central nervous system, testes, mediastinum i.e. areas of sanctuary or bulk disease.

♦ Informed consent must be obtained.

0 0

Post a comment